Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on August 25, 2008. The report details a regulatory milestone achieved by the Company's partner, Biosense Webster, Inc., regarding their joint development of ablation catheters for the Niobe Magnetic Navigation System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific operational event rather than financial performance.
Material Changes
The primary material change reported is the receipt of CE Mark approval by Biosense Webster, Inc. for the commercial sale of the magnetic irrigated catheter in Europe. This approval enables the commercialization of the device for treating complex left-sided arrhythmias, including atrial fibrillation, within the European market.
Outlook and Management Commentary
- Regulatory Status: The magnetic irrigated catheter has received CE Mark approval for Europe.
- Commercial Timeline: The Company expects clinical use to commence in the very near term as part of the partner's pre-launch evaluation.
- Application: The device is intended for the treatment of complex left-sided arrhythmias.
Investor Verification Checklist
- Confirm the specific timeline for the partner's pre-launch evaluation and commercial availability in Europe.
- Verify the commercial agreement terms between Stereotaxis and Biosense Webster regarding revenue sharing or royalties for the magnetic irrigated catheter.
- Assess the competitive landscape for magnetic navigation systems in the European market.